AntlerA Norrin/Wnt-agonist ANT antibody enters clinical trials through a strategic partnership with EyeBio
AntlerA Norrin/Wnt-agonist antibody, through a strategic partnership with EyeBio, has entered clinical trials for treatment of retinopathies.
AntlerA previously reported the development of a Norrin/Wnt-mimetic for treatment of leaky blood vessels in the eye.
“We are pleased to support EyeBio in the development and advancement of EYE103, a Norrin/Wnt-mimetic, into the clinic. Built based on AntlerA’s ANT-Pharm platform the tetravalent antibody molecule binds specifically to FZD4/LRP5 receptors leading to Wnt-signalling and restoration of blood vessel integrity in the eye,” said Dr Sekar Seshagiri, CEO, AntlerA Therapeutics.
He added: “This is a first-in class molecule for treatment of diabetic retinopathy and several paediatric retinal diseases such as FEVR/Norrie, Coats, and ROP.”
AntlerA Therapeutics is a regenerative medicines company focused on developing novel protein therapeutics that function by modulating Wnt signalling to harness the regenerative potential of tissue resident stem cells
